Akira Yabuno

Akira Yabuno

Auto-generated profile, based on publicly available information

Akira Yabuno

Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Gynecologic Oncology
Verified
Journal Article
Closed access
KMKoji Matsuo
Koji Matsuo
AYAkira Yabuno
Akira Yabuno
MHMarianne S. Hom
Marianne S. Hom
MSMasako Shida
Masako Shida
MKMamoru Kakuda
Mamoru Kakuda
LRLynda D. Roman
Lynda D. Roman

26 May 2020 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
HMHirokazu Matsushita
Hirokazu Matsushita
KHKosei Hasegawa
Kosei Hasegawa
KOKatsutoshi Oda
Katsutoshi Oda
SYShogo Yamamoto
Shogo Yamamoto
KAKayo Asada
Kayo Asada
KKKazuhiro Kakimi
Kazuhiro Kakimi
Background: There is increasing evidence for the benefit of poly ADP ribose polymerase (PARP) inhibitors in a subset of high-grade serous ovarian carcinoma (HGSC) patients, especially those with homologous recombination (HR)-deficient tumors. However, new treatment strategies, such as immune checkpoint inhibition, are required for patients with HR-proficient tumors. Methods: A total of 80 cases of HGSC were analyzed in this study. Whole exome and RNA sequencing was performed for these tumors. Methylation arrays were also carried out to examine BRCA1 and RAD51C promoter methylation status. Mutations, neoantigen load, antigen presentation machinery, and local immune profile were investigated, and the relationships of these factors with clinical outcome were also analyzed. Results: As expected, the numbers of predicted neoAgs were lower in HR-proficient (n=46) than HR-deficient tumors (n=34). However, 40% of the patients with HR-proficient tumors still had higher than median numbers of neoAgs and better survival than patients with lower numbers of neoAgs. Incorporation of human leukocyte antigen (HLA)-class I expression status into the survival analysis revealed that patients with both high neoAg numbers and high HLA-class I expression (neoAghiHLAhi) had the best progression-free survival (PFS) in HR-proficient HGSC (p=0.0087). Gene set enrichment analysis demonstrated that the genes for effector memory CD8 T cells, TH1 T cells, the interferon-γ response, and other immune-related genes, were enriched in these patients. Interestingly, this subset of patients also had better PFS (p=0.0015) and a more T-cell-inflamed tumor phenotype than patients with the same phenotype (neoAghiHLAhi) in HR-deficient HGSC. Conclusions: Our results suggest that immune checkpoint inhibitors might be an alternative to explore in HR-proficient cases which currently do not benefit from PARP inhibition.

1 October 2019 in Gynecologic Oncology
Verified
Journal Article
Closed access
KMKoji Matsuo
Koji Matsuo
JCJames C. Cripe
James C. Cripe
KKKatherine C Kurnit
Katherine C Kurnit
MKMichiko Kaneda
Michiko Kaneda
AGAudrey S. Garneau
Audrey S. Garneau
LRLynda D. Roman
Lynda D. Roman

1 January 2020 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
YIYuji Ikeda
Yuji Ikeda
SSSho Sato
Sho Sato
AYAkira Yabuno
Akira Yabuno
DSDaisuke Shintani
Daisuke Shintani
AOAiko Ogasawara
Aiko Ogasawara
KHKosei Hasegawa
Kosei Hasegawa
Ikeda Y, et al. J Gynecol Oncol. 2019 Jun;31:e93. https://doi.org/10.3802/jgo.2020.31.e93

1 January 2021 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
TMTakashi Motohashi
Takashi Motohashi
AYAkira Yabuno
Akira Yabuno
HMHirofumi Michimae
Hirofumi Michimae
TOTetsuro Ohishi
Tetsuro Ohishi
MNMiwa Nonaka
Miwa Nonaka
TTTsutomu Tabata
Tsutomu Tabata
Motohashi T, et al. J Gynecol Oncol. 2020 Dec;32(1):e9. https://doi.org/10.3802/jgo.2021.32.e9

1 January 2017 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
TNTadaaki Nishikawa
Tadaaki Nishikawa
KHKosei Hasegawa
Kosei Hasegawa
AYAkira Yabuno
Akira Yabuno
HYHiroyuki Yoshida
Hiroyuki Yoshida
MYMasanori Yasuda
Masanori Yasuda
KFKeiichi Fujiwara
Keiichi Fujiwara
Nishikawa T, et al. J Gynecol Oncol. 2016 Aug;28(1):e25. https://doi.org/10.3802/jgo.2017.28.e25